Armata Pharmaceuticals Inc. Common Stock (ARMP)
Stock · AMEX · Health Care
$3.35as of 10/16/2026
Price chart
Active signals
ARMP Signal Track Record
How signals performed across all stocks →What ARMP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -3.2% | 44% | September 14, 2026 |
| Bollinger Band Breakout | 25 | -5.9% | 40% | August 25, 2026 |
| Bollinger Band Breakdown | 18 | +5.0% | 61% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 11 | +1.0% | 55% | June 24, 2026 |
| Any 20-session window (baseline) | -1.5% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARMP
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa.…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 61
- Website
- www.armatapharma.com/
Fundamentals
- 1-day range
- $3.01$3.42
- Market cap
- $172.54M
- P/E (trailing)
- —
- P/E (forward)
- -1.65
- EPS (trailing)
- $-6.12
- Dividend yield
- —
- Beta
- 1.66
- Avg. volume
- 200.4K
- Dividend pay date
- May 10, 2019
Forecasts
2 analyst ratings
Armata Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARMPArmata Pharmaceuticals Inc. Common Stock$3.37▲ 9.06%Market cap $172.54MP/E —$2.75$16.34
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- OTLKOutlook Therapeutics Inc. Common Stock$0.488▼ 2.40%Market cap $181.85MP/E —$0.1611$2.54
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARMP Armata Pharmaceuticals Inc. Common Stock | $172.54M | — | $3.37 | ▲ 9.06% | $2.75$16.34 |
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| OTLK Outlook Therapeutics Inc. Common Stock | $181.85M | — | $0.488 | ▼ 2.40% | $0.1611$2.54 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Armata Pharmaceuticals Announces Two U.S. Patents Covering AP-SA02 And AP-PA02 Phage Therapies, With Protection Until At Least 2041benzinga · 10/7/2026
- Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United StatesYahoo · 10/7/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/23/2026
- Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial ProgramBenzinga · 9/23/2026
- Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 DevelopmentYahoo · 9/23/2026
- HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price TargetBenzinga · 9/23/2026
- Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02Benzinga · 9/23/2026
- Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical IsolatesYahoo · 9/21/2026
- What's going on in today's after hours sessionChartMill · 9/14/2026
Insider Activity
Insider Actions →- Deborah Birx · July 10, 2026 · Tax Withholding14.0K @ $4.26
- Gilmer Daniel B. · April 24, 2026 · Grant51.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.86M
- Total value held
- $39.37M
- Institutional holders
- 43
- Unknown2.11M
- Unknown366.0K
- Unknown258.0K
- Unknown137.0K
- Unknown114.6K
- Unknown100.0K
- Unknown90.6K
- Unknown74.2K
- Unknown65.0K
- Unknown64.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial
Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial. Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.